| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
(Z)-2-Carboxy-4,6-dichloroindole-3-(2'-phenyl-2'-carboxy)-ene manufacturers
- MDL 105519
-
- $99.00
-
2026-05-11
- CAS:161230-88-2
- Purity: 99.67%
- Supply Ability: 10g
|
| | (Z)-2-Carboxy-4,6-dichloroindole-3-(2'-phenyl-2'-carboxy)-ene Basic information |
| Product Name: | (Z)-2-Carboxy-4,6-dichloroindole-3-(2'-phenyl-2'-carboxy)-ene | | Synonyms: | MDL-105212;MDL 105,519;3-[(1E)-2-Carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid;1H-Indole-2-carboxylic acid, 3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-;MDL 105,519 >=98% (HPLC), solid;(Z)-2-Carboxy-4,6-dichloroindole-3-(2'-phenyl-2'-carboxy)-ene | | CAS: | 161230-88-2 | | MF: | C18H11Cl2NO4 | | MW: | 376.19 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | (Z)-2-Carboxy-4,6-dichloroindole-3-(2'-phenyl-2'-carboxy)-ene Chemical Properties |
| Boiling point | 601.3±55.0 °C(Predicted) | | density | 1.594±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 5 mg/mL | | pka | 3.20±0.19(Predicted) | | form | solid | | color | white | | InChI | 1S/C18H11Cl2NO4/c19-10-6-13(20)15-12(16(18(24)25)21-14(15)7-10)8-11(17(22)23)9-4-2-1-3-5-9/h1-8,21H,(H,22,23)(H,24,25)/b11-8- | | InChIKey | LPWVUDLZUVBQGP-FLIBITNWSA-N | | SMILES | OC(=O)C(=C/c1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O)\c3ccccc3 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | (Z)-2-Carboxy-4,6-dichloroindole-3-(2'-phenyl-2'-carboxy)-ene Usage And Synthesis |
| Uses | MDL 105519 is a potent and selective antagonist of glycine binding to the NMDA receptor. | | Biochem/physiol Actions | MDL 105,519 is a high affinity N-methyl-D-aspartate (NMDA) glutamate receptor antagonist at the glycine site. It inhibits NMDA-dependent responses. | | in vivo | MDL 105519 is an NMDA receptor antagonistin vivo. Intravenously administration of MDL 105519 prevents harmaline-stimulated increases in cerebellar cyclic GMP content, providing biochemical evidence of NMDA receptor antagonism in vivo. This antagonism is associated with anticonvulsant activity in genetically based, chemically induced, and electrically mediated seizure models. Anxiolytic activity is observed in the rat separation-induced vocalization model, but muscle-relaxant activity is apparent at lower doses. Higher doses impair rotorod performance, but are without effect on mesolimbic dopamine turnover or prepulse inhibition of the startle reflex[1]. | | IC 50 | NMDA Receptor | | References | [1] Baron BM, et al. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol. 1997 Apr 4;323(2-3):181-92. DOI:10.1016/s0014-2999(97)00045-9 |
| | (Z)-2-Carboxy-4,6-dichloroindole-3-(2'-phenyl-2'-carboxy)-ene Preparation Products And Raw materials |
|